Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma — Stella

Home/Neuroblastoma/

View on ClinicalTrials.gov

Recruiting

Back to Neuroblastoma trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(2 sites)

China

West China Hospital, Chengdu, Sichuang

West China Hospital, Chengdu

Key details

Phase

Very early testing

Sponsor

Sichuan University

Enrollment target

~10 participants

Started

July 2025

Primary completion

June 2026

Age range

12 Months and older

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.